Pathophysiology: What Happens During Myocardial Ischemia
To fully understand the mechanism of action, it is necessary to examine the metabolic disorders that occur in the heart muscle during oxygen deprivation. Under ischemic conditions, the following pathological cascade is triggered:
- Energy starvation: ATP synthesis drops sharply.
- Ionic imbalance: Energy deficiency disrupts ATP-dependent potassium channels, leading to a global failure of transmembrane transport for key ions (potassium, sodium, and calcium).
- Acidosis: Attempting to compensate for the lack of energy, the cell enhances anaerobic glycolysis, inevitably leading to intracellular acidification.
- Cytotoxicity: Fatty acid oxidation is activated, provoking a massive accumulation of free radicals that directly damage cardiomyocytes.
Mechanism of Action (Pharmacodynamics)
The pharmacodynamics of trimetazidine is based on the optimization of cellular energy metabolism. The site of action is inside the mitochondria.
- Enzyme inhibition: The drug selectively blocks the 3-ketoacyl-CoA thiolase enzyme.
- Biochemical shift: Blocking this enzyme suppresses $\beta$-oxidation of fatty acids. In response, cardiomyocyte metabolism switches to an alternative pathway—glucose oxidation.
- End result: The glucose breakdown process requires significantly less oxygen to synthesize the exact same amount of ATP. This ensures more efficient energy production under hypoxic conditions.
Cellular Effects and Clinical Outcome
Restoring intracellular ATP stores triggers a chain of positive tissue changes:
- Normalization of ionic homeostasis: Ion pumps resume function, pathological cellular overload with sodium and calcium ions is reduced, and potassium concentration normalizes. The main result is improved myocardial contractility.
- Combatting acidosis: Activation of aerobic glycolysis significantly reduces intracellular acidification.
- Cytoprotection: Inhibition of fat oxidation naturally decreases the production of destructive free radicals.
In clinical practice, it is important to note that trimetazidine does not affect overall hemodynamics (does not alter blood pressure or heart rate) or myocardial blood supply. In patients with angina pectoris, it reduces the frequency of attacks, increases exercise tolerance, and lowers the need for nitrates.
Pharmacokinetics and Place in Therapy
The drug is well absorbed from the gastrointestinal tract and easily crosses histohematic barriers. Its plasma protein binding is extremely low at approximately 1%. It undergoes minimal metabolism and is excreted predominantly by the kidneys. With a standard dosing regimen (20 mg three times daily), a steady-state therapeutic concentration in the blood is reached within 24 hours.
In modern medicine, trimetazidine is used as part of combination therapy for ischemic heart disease (IHD). To prevent severe complications such as myocardial infarction, it is prescribed alongside:
- Antiplatelet agents (acetylsalicylic acid, clopidogrel);
- Lipid-lowering agents (statins: simvastatin, pravastatin).
Treatment is well tolerated; adverse effects are rare and mostly limited to mild gastrointestinal disturbances.